What can we learn about CLL by studying environmental stimuli?
Why the rapid development of new drugs poses new challenges
ASH highlights in CLL and lymphoma by Dr Andrew Zelenetz
Promising CLL & FL data from ICML 2017: BGB-3111 and obinituzumab
Overview of 3 studies on CLL therapy: data on ibrutinib and a ROR1 inhibitor